![]() |
Acta Pharmacologica Sinica (2009) 30: 653-655; doi: 10.1038/aps.2009.89 |
| Preface | [ Full text ] |
| Understanding of nicotinic acetylcholine receptors
|
Jie WU* |
Barrow Neurological Institute, St Joseph’s
Hospital and Medical Center, Phoenix, AZ 85013, USA
|
Cigarette smoking is a major public health problem
and has been identified as the second-most prevalent cause of death in the
world.
Nicotine is the major biologically active substance
that promotes the use of tobacco products. Nicotine exerts its biological effects through nicotinic acetylcholine
receptors (nAChRs). nAChRs are prototypical members of the ligand-gated ion channel superfamily of neurotransmitter receptors[4]. nAChRs represent both classic and contemporary models for the establishment of
concepts pertaining to mechanisms of drug action, synaptic transmission, and
structural/functional diversity of transmembrane signaling molecules[4]. Neuronal nAChRs are found throughout the
central nervous system and exist as multiple, diverse subtypes of pentameric structures with unique combinations from at
least twelve (α2–?0, β2–?) genetically-distinct subunits[5]. Binding by endogenous (acetylcholine) or
exogenous (nicotine) agonists to nAChR opens an
intrinsic ion channel in the receptor, allowing the flow of cation ions (Na+, Ca2+, and K+) through the cell
membrane, and inducing a wide variety of biological responses. Accumulating
lines of evidence demonstrate that nAChRs play
critical roles in mediating nicotine reward, dependence and addiction[6,
7]. In addition, alterations
of nAChRs have been found in various diseases such as
Parkinson’s diseases, Alzheimer’s disease, schizophrenia, depression, epilepsy,
diabetes, respiration disorders and some immunological disorders[8]. Therefore, understanding the molecular
biology, physiology, pharmacology and pathophysiology of neuronal nAChRs will significantly improve the
diagnosis, prevention and treatment of these diseases and pathological
conditions, including nicotine addiction.
Until recently, much of our understanding of the
physiology and pharmacology of neuronal nAChRs has
come from heterologous expression studies. Principally using Xenopus oocytes as hosts,
but also using transfected mammalian cells, these
efforts have helped to define the realm of possibilities for nAChR subunit combinations that can form functional channels[9]. A variety of experimental
approaches have been employed in the study of natively-expressed nAChRs, including molecular and cellular biology,
electrophysiology, neurotransmitter release analyses, isotopic ion flux
studies, immunochemistry, neuroanatomy, calcium
imaging and behavioral testing. Studies using transgenic mice have helped to
identify subunits that constitute some native, functional nAChR subtypes. Recently, significant
insights have been gained regarding the molecular, cellular and system basis of nAChR function in the brain. For instance, at the atomic and
molecular level, X-ray crystallographic structures of acetylcholine binding
proteins (AChBPs) are providing new answers to
questions about how nAChRs function as biophysical
machines, and as participants in cellular and systems physiology[10]. The studies of structure-function
relationships have revealed that the structures of different nAChRs with different pharmacological profiles and kinetics
will help to illustrate how agonists and antagonists bind to orthosteric binding sites, how allosteric modulators alter receptor function by binding outside these sites, how nAChRs gate ion flow, and how nAChR cytoplasmic domains affect receptor function[4, 11, 12]. At the level of cellular and system
biology, the functional subtypes of native nAChRs have been identified in different brain areas and their roles in the mediation
of nicotine reward, dependence and addiction are beginning to be elucidated[5, 13, 14] Particularly,
nicotine-induced neuronal adaptations (nAChR up-regulation and synaptic plasticity) in the brain reward center (ventral tegmental area) have been postulated as an important
cellular mechanism of nicotine reinforcement[15-17]. At the behavioral level, nicotine
self-administration experiments combined with nAChR subunit knockout mice have provided important evidence concerning which nAChR subtypes are crucial for nicotine seeking behavior[7, 18, 19]. Finally, based on the above experimental
data, some theoretical models of nAChR-associated
signal pathways and neuronal circuits have been proposed to interpret the roles
of nAChRs in addiction, neurodegeneration,
and mental illnes[20-22].
Collectively, multiple findings indicate that nAChRs in the
brain play roles not only in the mediation of classical, excitatory,
cholinergic neurotransmission at selected loci, but also, and perhaps more
globally, in the modulation of neurotransmission by other chemical messengers,
including glutamate, GABA, the monoamines, including dopamine, norepinephrine and serotonin, and acetylcholine (ACh) itself. This means that some nAChR subtypes have postsynaptic (or peri-synaptic), somatodendritic localizations, whereas others have
pre-synaptic dispositions. Moreover, some nAChRs have been implicated in
processes such as structuring and maintenance of neurites and synapses. Thus, nAChRs may play complex and important roles in neuronal
function and in neurological and psychological diseases.
In this nAChR-themed
issue, I bring together many of world’s leading researchers in the nAChR research field to provide state-of-the-art reviews,
and original research articles, covering a wide range of nAChR-related
areas. These articles span from
molecular to behavioral investigations involving different experimental
techniques such as molecular/cell biology, biophysics, electrophysiology,
receptor pharmacology and behavioral testing. The articles in this specific issue
provide a broad perspective on current advances in nAChR studies. I hope this issue will
provide a foundation for future developments in nAChR research. In particular, I
sincerely hope that this specific issue will promote the further engagement of
Chinese scientists in nAChR-related research, smoking
cessation efforts, and the management of smoking-associated diseases in
China.
|
The work was
supported by a program for Changjiang Scholars and the Innovative Research Team
in University (No PCSIRT), NCET Foundation, NSFC (No 30725045),
National 863 Program (No 2006AA02Z338), China Postdoctoral Science
Foundation (No 20070410711), ?
|
|
[ Full text ] |
Copyright©APS 2009 Add: 294 Tai-Yuan Road, Shanghai 200031, China Phn: 86-21-5492-2821 Fax: 86-21-5492-2823 E-mail: aps@mail.shcnc.ac.cn |